Molecular networks that regulate cancer metastasis

Seminars in Cancer Biology

Volumn 22, Issue 3, 2012, Pages 234-249

  Spano, Daniela ^a,b   Heck, Chantal ^c   De Antonellis, Pasqualino ^a,b   Christofori, Gerhard ^c   Zollo, Massimo ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Amoeboid; Extravasation; Intravasation; Invasion; Lymphogenic; Mesenchymal; Metastatic outgrowth; Microenvironment

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANASTROZOLE; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; IMATINIB; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; OXALIPLATIN; PREDNISONE; RAPAMYCIN; RESVERATROL; RIDAFOROLIMUS; RITUXIMAB; TANESPIMYCIN; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

BLOOD BRAIN BARRIER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CELL ADHESION; CELL MIGRATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRAVASATION; GENE REGULATORY NETWORK; HUMAN; METASTASIS INHIBITION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENE EXPRESSION; GENE REGULATORY NETWORKS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84861185907     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.03.006     Document Type: Review

References (183)

1. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nature Reviews Cancer 2006, 6:449-458.
2. Monteiro J., Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. European Journal of Cancer 2010, 46:1198-1203.
3. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer 2009, 9:274-284.
4. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews 1989, 8:98-101.
5. Ewing J. The general pathological conception of cancer. Canadian Medical Association journal 1935, 33:125-135.
6. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
7. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
8. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
9. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Reviews Cancer 2003, 3:362-374.
10. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
11. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nature Reviews Cancer 2005, 5:744-749.
12. Wicki A., Christofori G. The potential role of podoplanin in tumour invasion. British Journal of Cancer 2007, 96:1-5.
13. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Reviews 2009, 28:15-33.
14. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 2009, 119:1420-1428.
15. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer 2009, 9:265-273.
16. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
17. Friedl P., Wolf K. Plasticity of cell migration: a multiscale tuning model. The Journal of Cell Biology 2010, 188:11-19.
18. Yilmaz M., Christofori G. Mechanisms of motility in metastasizing cells. Molecular Cancer Research 2010, 8:629-642.
19. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005, 179:56-65.
20. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 2008, 68:989-997.
21. Tarin D., Thompson E.W., Newgreen D.F. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Research 2005, 65:5996-6000. [discussion -1].
22. Thomas P.A., Kirschmann D.A., Cerhan J.R., Folberg R., Seftor E.A., Sellers T.A., et al. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1999, 5:2698-2703.
23. Hlubek F., Brabletz T., Budczies J., Pfeiffer S., Jung A., Kirchner T. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. International Journal of Cancer 2007, 121:1941-1948.
24. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research 2009, 69:4116-4124.
25. Pankova K., Rosel D., Novotny M., Brabek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cellular and Molecular Life Sciences 2010, 67:63-71.
26. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
27. Sanz-Moreno V., Gaggioli C., Yeo M., Albrengues J., Wallberg F., Viros A., et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011, 20:229-245.
28. Pinner S., Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nature Cell Biology 2008, 10:127-137.
29. Sidani M., Wessels D., Mouneimne G., Ghosh M., Goswami S., Sarmiento C., et al. Cofilin determines the migration behavior and turning frequency of metastatic cancer cells. The Journal of Cell Biology 2007, 179:777-791.
30. Garzia L., D'Angelo A., Amoresano A., Knauer S.K., Cirulli C., Campanella C., et al. Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility. Oncogene 2008, 27:1853-1864.
31. Kobayashi T., Hino S., Oue N., Asahara T., Zollo M., Yasui W., et al. Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Molecular and Cellular Biology 2006, 26:898-911.
32. Muller T., Stein U., Poletti A., Garzia L., Rothley M., Plaumann D., et al. ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients. Oncogene 2010, 29:2393-2403.
33. Steeg P.S., Zollo M., Wieland T. A critical evaluation of biochemical activities reported for the nucleoside diphosphate kinase/Nm23/Awd family proteins: opportunities and missteps in understanding their biological functions. Naunyn-Schmiedebergs Archives of Pharmacology 2011, 384:331-339.
34. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nature Reviews Molecular Cell Biology 2009, 10:445-457.
35. Kerkela E., Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Experimental Dermatology 2003, 12:109-125.
36. Hegerfeldt Y., Tusch M., Brocker E.B., Friedl P. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Research 2002, 62:2125-2130.
37. Fidler I.J. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. European Journal of Cancer 1973, 9:223-227.
38. Friedl P., Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Research 2008, 68:7247-7249.
39. Wolf K., Friedl P. Mapping proteolytic cancer cell-extracellular matrix interfaces. Clinical & Experimental Metastasis 2009, 26:289-298.
40. Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. The American Journal of Pathology 2005, 166:913-921.
41. Wicki A., Lehembre F., Wick N., Hantusch B., Kerjaschki D., Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006, 9:261-272.
42. Scholl F.G., Gamallo C., Vilaro S., Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. Journal of Cell Science 1999, 112(Pt 24):4601-4613.
43. Atsumi N., Ishii G., Kojima M., Sanada M., Fujii S., Ochiai A. Podoplanin a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochemical and Biophysical Research Communications 2008, 373:36-41.
44. Martin-Villar E., Megias D., Castel S., Yurrita M.M., Vilaro S., Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. Journal of Cell Science 2006, 119:4541-4553.
45. Poujade M., Grasland-Mongrain E., Hertzog A., Jouanneau J., Chavrier P., Ladoux B., et al. Collective migration of an epithelial monolayer in response to a model wound. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:15988-15993.
46. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nature Cell Biology 2007, 9:1392-1400.
47. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nature Reviews Cancer 2009, 9:239-252.
48. Zumsteg A., Christofori G. Corrupt policemen: inflammatory cells promote tumor angiogenesis. Current Opinion in Oncology 2009, 21:60-70.
49. Spano D., Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clinica Experimental Metastasis 2012, 29(4):381-395.
50. Zhang Y., Tang H., Cai J., Zhang T., Guo J., Feng D., et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Letters 2011, 303:47-55.
51. Kobayashi Y. The role of chemokines in neutrophil biology. Frontiers in Bioscience: A Journal and Virtual Library 2008, 13:2400-2407.
52. Bockhorn M., Roberge S., Sousa C., Jain R.K., Munn L.L. Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Research 2004, 64:2469-2473.
53. Cao Z., Henzel W.J., Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996, 271:1128-1131.
54. Li S., Strelow A., Fontana E.J., Wesche H. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:5567-5572.
55. Muzio M., Ni J., Feng P., Dixit V.M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278:1612-1615.
56. Behrens C., Feng L., Kadara H., Kim H.J., Lee J.J., Mehran R., et al. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:34-44.
57. Boye K., Grotterod I., Aasheim H.C., Hovig E., Maelandsmo G.M. Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. International Journal of Cancer 2008, 123:1301-1310.
58. Forst B., Hansen M.T., Klingelhofer J., Moller H.D., Nielsen G.H., Grum-Schwensen B., et al. Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. PLoS One 2010, 5:e10374.
59. Grum-Schwensen B., Klingelhofer J., Grigorian M., Almholt K., Nielsen B.S., Lukanidin E., et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Research 2010, 70:936-947.
60. Klingelhofer J., Moller H.D., Sumer E.U., Berg C.H., Poulsen M., Kiryushko D., et al. Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein. The FEBS Journal 2009, 276:5936-5948.
61. Mishra P., Banerjee D., Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. Journal of Leukocyte Biology 2011, 89:31-39.
62. Hembruff S.L., Jokar I., Yang L., Cheng N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms. Neoplasia 2010, 12:425-433.
63. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Research 2007, 67:9417-9424.
64. Loberg R.D., Ying C., Craig M., Yan L., Snyder L.A., Pienta K.J. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007, 9:556-562.
65. Lu X., Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. The Journal of Biological Chemistry 2009, 284:29087-29096.
66. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
67. Mirolo M., Fabbri M., Sironi M., Vecchi A., Guglielmotti A., Mangano G., et al. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. European Cytokine Network 2008, 19:119-122.
68. Zollo M., Di Dato V., Spano D., De Martino D., Liguori D., Marino N., et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 2012, 10.1007/s10585-012-9473-5.
69. Balkwill F. Cancer and the chemokine network. Nature Reviews Cancer 2004, 4:540-550.
70. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of Leukocyte Biology 2009, 86:1065-1073.
71. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Research 2007, 67:10019-10026.
72. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. The Journal of Experimental Medicine 2008, 205:2235-2249.
73. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. Journal of Immunology 2008, 181:4666-4675.
74. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
75. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
76. Melani C., Chiodoni C., Forni G., Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145.
77. Abraham S.N., St John A.L. Mast cell-orchestrated immunity to pathogens. Nature Reviews Immunology 2010, 10:440-452.
78. Kim B.G., Li C., Qiao W., Mamura M., Kasprzak B., Anver M., et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006, 441:1015-1019.
79. Mekori Y.A., Metcalfe D.D. Mast cell-T cell interactions. Journal of Allergy and Clinical Immunology 1999, 104:517-523.
80. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nature Reviews Cancer 2006, 6:392-401.
81. Goswami S., Sahai E., Wyckoff J.B., Cammer M., Cox D., Pixley F.J., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Research 2005, 65:5278-5283.
82. Pollard J.W. Macrophages define the invasive microenvironment in breast cancer. Journal of Leukocyte Biology 2008, 84:623-630.
83. Ojalvo L.S., Whittaker C.A., Condeelis J.S., Pollard J.W. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. Journal of Immunology 2010, 184:702-712.
84. Pukrop T., Klemm F., Hagemann T., Gradl D., Schulz M., Siemes S., et al. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5454-5459.
85. Conti P., Castellani M.L., Kempuraj D., Salini V., Vecchiet J., Tete S., et al. Role of mast cells in tumor growth. Annals of Clinical and Laboratory Science 2007, 37:315-322.
86. Hagemann T., Robinson S.C., Schulz M., Trumper L., Balkwill F.R., Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004, 25:1543-1549.
87. Vasiljeva O., Papazoglou A., Kruger A., Brodoefel H., Korovin M., Deussing J., et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Research 2006, 66:5242-5250.
88. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
89. Ceteci F., Ceteci S., Karreman C., Kramer B.W., Asan E., Gotz R., et al. Disruption of tumor cell adhesion promotes angiogenic switch and progression to micrometastasis in RAF-driven murine lung cancer. Cancer Cell 2007, 12:145-159.
90. Png K.J., Halberg N., Yoshida M., Tavazoie S.F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011, 481:190-194.
91. Gaziel-Sovran A., Segura M.F., Di Micco R., Collins M.K., Hanniford D., Vega-Saenz de Miera E., et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011, 20:104-118.
92. Le X.F., Merchant O., Bast R.C., Calin G.A. The roles of microRNAs in the cancer invasion-metastasis cascade. Cancer Microenvironment 2010, 3:137-147.
93. Poschke I., Mougiakakos D., Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunology, Immunotherapy: CII 2011, 60:1161-1171.
94. Wilke C.M., Wei S., Wang L., Kryczek I., Kao J., Zou W. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunology 2011, 60:1529-1541.
95. Mumm J.B., Emmerich J., Zhang X., Chan I., Wu L., Mauze S., et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 2011, 20:781-796.
96. Watkins S.K., Zhu Z., Riboldi E., Shafer-Weaver K.A., Stagliano K.E., Sklavos M.M., et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. The Journal of Clinical Investigation 2011, 121:1361-1372.
97. Bockhorn M., Jain R.K., Munn L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed. Lancet Oncology 2007, 8:444-448.
98. Butler T.P., Gullino P.M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Research 1975, 35:512-516.
99. Klein C.A. Parallel progression of primary tumours and metastases. Nature Reviews Cancer 2009, 9:302-312.
100. Podsypanina K., Du Y.C., Jechlinger M., Beverly L.J., Hambardzumyan D., Varmus H. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008, 321:1841-1844.
101. Husemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68.
102. Stoecklein N.H., Hosch S.B., Bezler M., Stern F., Hartmann C.H., Vay C., et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008, 13:441-453.
103. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nature Reviews Drug Discovery 2011, 10:417-427.
104. van Zijl F., Krupitza G., Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutation Research 2011, 728:23-34.
105. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Research 2007, 67:2649-2656.
106. Boimel P.J., Smirnova T., Zhou Z.N., Wyckoff J., Park H.I., Coniglio S.J., et al. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Research 2012, 14:R23.
107. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
108. Hernandez L., Magalhaes M.A., Coniglio S.J., Condeelis J.S., Segall J.E. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Research 2011, 13:R128.
109. Buxton I.L., Yokdang N., Matz R.M. Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. Cancer Letters 2010, 291:131-141.
110. Bonnomet A., Brysse A., Tachsidis A., Waltham M., Thompson E.W., Polette M., et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. Journal of Mammary Gland Biology and Neoplasia 2010, 15:261-273.
111. Labelle M., Schnittler H.J., Aust D.E., Friedrich K., Baretton G., Vestweber D., et al. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Research 2008, 68:1388-1397.
112. Nierodzik M.L., Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10:355-362.
113. Im J.H., Fu W., Wang H., Bhatia S.K., Hammer D.A., Kowalska M.A., et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Research 2004, 64:8613-8619.
114. Kunita A., Kashima T.G., Morishita Y., Fukayama M., Kato Y., Tsuruo T., et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. The American Journal of Pathology 2007, 170:1337-1347.
115. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
116. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
117. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
118. Sonoshita M., Aoki M., Fuwa H., Aoki K., Hosogi H., Sakai Y., et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 2011, 19:125-137.
119. Giampieri S., Manning C., Hooper S., Jones L., Hill C.S., Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nature Cell Biology 2009, 11:1287-1296.
120. Padua D., Zhang X.H., Wang Q., Nadal C., Gerald W.L., Gomis R.R., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
121. Albrecht I., Christofori G. Molecular mechanisms of lymphangiogenesis in development and cancer. International Journal of Developmental Biology 2011, 55:483-494.
122. Alitalo K., Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1:219-227.
123. Saharinen P., Petrova T.V. Molecular regulation of lymphangiogenesis. Annals of the New York Academy of Sciences 2004, 1014:76-87.
124. Burton J.B., Priceman S.J., Sung J.L., Brakenhielm E., An D.S., Pytowski B., et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Research 2008, 68:7828-7837.
125. Crnic I., Strittmatter K., Cavallaro U., Kopfstein L., Jussila L., Alitalo K., et al. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Research 2004, 64:8630-8638.
126. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. Journal of the National Cancer Institute 2002, 94:819-825.
127. Krishnan J., Kirkin V., Steffen A., Hegen M., Weih D., Tomarev S., et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Research 2003, 63:713-722.
128. Lin J., Lalani A.S., Harding T.C., Gonzalez M., Wu W.W., Luan B., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Research 2005, 65:6901-6909.
129. Wong S.Y., Haack H., Crowley D., Barry M., Bronson R.T., Hynes R.O. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Research 2005, 65:9789-9798.
130. Brideau G., Makinen M.J., Elamaa H., Tu H., Nilsson G., Alitalo K., et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Research 2007, 67:11528-11535.
131. Caunt M., Mak J., Liang W.C., Stawicki S., Pan Q., Tong R.K., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13:331-342.
132. Sini P., Samarzija I., Baffert F., Littlewood-Evans A., Schnell C., Theuer A., et al. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics. Cancer Research 2008, 68:1581-1592.
133. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Research 2005, 65:4739-4746.
134. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
135. Ristimaki A., Narko K., Enholm B., Joukov V., Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. The Journal of Biological Chemistry 1998, 273:8413-8418.
136. Tsai P.W., Shiah S.G., Lin M.T., Wu C.W., Kuo M.L. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. The Journal of Biological Chemistry 2003, 278:5750-5759.
137. Orlandini M., Marconcini L., Ferruzzi R., Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:11675-11680.
138. Shields J.D., Fleury M.E., Yong C., Tomei A.A., Randolph G.J., Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007, 11:526-538.
139. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
140. Cabioglu N., Yazici M.S., Arun B., Broglio K.R., Hortobagyi G.N., Price J.E., et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2005, 11:5686-5693.
141. Takeuchi H., Fujimoto A., Tanaka M., Yamano T., Hsueh E., Hoon D.S. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clinical Cancer Research 2004, 10:2351-2358.
142. Gunther K., Leier J., Henning G., Dimmler A., Weissbach R., Hohenberger W., et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of chemokine receptor CCR7. International Journal of Cancer 2005, 116:726-733.
143. Wang J., Xi L., Gooding W., Godfrey T.E., Ferris R.L. Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. Advances in Otorhinolaryngology 2005, 62:121-133.
144. Heresi G.A., Wang J., Taichman R., Chirinos J.A., Regalado J.J., Lichtstein D.M., et al. Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urologic Oncology 2005, 23:261-267.
145. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. International Journal of Cancer 2003, 105:186-189.
146. Ding Y., Shimada Y., Maeda M., Kawabe A., Kaganoi J., Komoto I., et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2003, 9:3406-3412.
147. Mashino K., Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Research 2002, 62:2937-2941.
148. Madlener S., Saiko P., Vonach C., Viola K., Huttary N., Stark N., et al. Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro. British Journal of Cancer 2010, 102:1361-1370.
149. Scheel C., Onder T., Karnoub A., Weinberg R.A. Adaptation versus selection: the origins of metastatic behavior. Cancer Research 2007, 67:11476-11479. [discussion 9-80].
150. Price J.T., Thompson E.W. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opinion on Therapeutic Targets 2002, 6:217-233.
151. Stoletov K., Kato H., Zardouzian E., Kelber J., Yang J., Shattil S., et al. Visualizing extravasation dynamics of metastatic tumor cells. Journal of Cell Science 2010, 123:2332-2341.
152. Huh S.J., Liang S., Sharma A., Dong C., Robertson G.P. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Research 2010, 70:6071-6082.
153. Nieswandt B., Hafner M., Echtenacher B., Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research 1999, 59:1295-1300.
154. Palumbo J.S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Seminars in Thrombosis and Hemostasis 2008, 34:154-160.
155. Erpenbeck L., Schon M.P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010, 115:3427-3436.
156. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nature Reviews Cancer 2011, 11:123-134.
157. Sierko E., Wojtukiewicz M.Z. Inhibition of platelet function: does it offer a chance of better cancer progression control. Seminars in Thrombosis and Hemostasis 2007, 33:712-721.
158. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590.
159. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. Journal of the National Cancer Institute 1999, 91:22-36.
160. Bae J.S., Lee S.H., Kim J.E., Choi J.Y., Park R.W., Yong Park J., et al. Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through alpha3beta1 integrin. Biochemical and Biophysical Research Communications 2002, 294:940-948.
161. Kim J.E., Kim S.J., Jeong H.W., Lee B.H., Choi J.Y., Park R.W., et al. RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene 2003, 22:2045-2053.
162. Ma C., Rong Y., Radiloff D.R., Datto M.B., Centeno B., Bao S., et al. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes & Development 2008, 22:308-321.
163. Weis S., Cui J., Barnes L., Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology 2004, 167:223-229.
164. Coughlin S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. Journal of Thrombosis and Haemostasis 2005, 3:1800-1814.
165. Gavard J., Gutkind J.S. Protein kinase C-related kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from Galpha12/13 and Galpha11/q. The Journal of Biological Chemistry 2008, 283:29888-29896.
166. Steeg P.S., Camphausen K.A., Smith Q.R. Brain metastases as preventive and therapeutic targets. Nature Reviews Cancer 2011, 11:352-363.
167. Zhang C., Yu D. Microenvironment determinants of brain metastasis. Cell Bioscience 2011, 1:8.
168. Kienast Y., von Baumgarten L., Fuhrmann M., Klinkert W.E., Goldbrunner R., Herms J., et al. Real-time imaging reveals the single steps of brain metastasis formation. Nature Medicine 2010, 16:116-122.
169. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
170. Lee K.Y., Kim Y.J., Yoo H., Lee S.H., Park J.B., Kim H.J. Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. Anticancer Research 2011, 31:4307-4313.
171. Lorger M., Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. The American Journal of Pathology 2010, 176:2958-2971.
172. Marchetti D., Li J., Shen R. Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Research 2000, 60:4767-4770.
173. Marchetti D., Aucoin R., Blust J., Murry B., Greiter-Wilke A. p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. Journal of Cellular Biochemistry 2004, 91:206-215.
174. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer 2011, 128:2527-2535.
175. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology 2006, 8:1369-1375.
176. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
177. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nature Cell Biology 2008, 10:1349-1355.
178. Lin E.Y., Jones J.G., Li P., Zhu L., Whitney K.D., Muller W.J., et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. The American Journal of Pathology 2003, 163:2113-2126.
179. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35-44.
180. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Medicine 2011, 17:867-874.
181. Moller H.D., Ralfkjaer U., Cremers N., Frankel M., Pedersen R.T., Klingelhofer J., et al. Role of fibulin-5 in metastatic organ colonization. Molecular Cancer Research 2011, 9:553-563.
182. Bellahcene A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nature Reviews Cancer 2008, 8:212-226.
183. Wai P.Y., Kuo P.C. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Reviews 2008, 27:103-118.